dvt prophylaxis in orthopedic surgeries
TRANSCRIPT
![Page 1: DVT PROPHYLAXIS IN ORTHOPEDIC SURGERIES](https://reader035.vdocuments.mx/reader035/viewer/2022062412/5871114f1a28abac6d8b5d4b/html5/thumbnails/1.jpg)
DVT PROPHYLAXIS IN ORTHOPEDIC SURGERIES
PRESENTED BY –DR SOUVIK PAULMODERATED BY –DR PRINCE RAINA
![Page 2: DVT PROPHYLAXIS IN ORTHOPEDIC SURGERIES](https://reader035.vdocuments.mx/reader035/viewer/2022062412/5871114f1a28abac6d8b5d4b/html5/thumbnails/2.jpg)
What Is Deep Vein Thrombosis ?
![Page 3: DVT PROPHYLAXIS IN ORTHOPEDIC SURGERIES](https://reader035.vdocuments.mx/reader035/viewer/2022062412/5871114f1a28abac6d8b5d4b/html5/thumbnails/3.jpg)
INTRODUCTION • WHAT IS VTE ?
• includes spectrum of deep vein thrombosis (DVT) and pulmonary embolism (PE).
![Page 4: DVT PROPHYLAXIS IN ORTHOPEDIC SURGERIES](https://reader035.vdocuments.mx/reader035/viewer/2022062412/5871114f1a28abac6d8b5d4b/html5/thumbnails/4.jpg)
NEED OF DVT PROPHYLAXIS
.common preventable cause of hospital deaths
DVT in traumatic injuries 5 - 63%
Without prophylaxis
venous thrombosis -- 50% Orthopedic surgeries
Fatal PE in 2.0% of total hip arthroplasty
Fatal PE in 2.5-7.5% of Fractured Hip
Ref: Campbell 12th edition Piotrowski JJ, et al Am J Surg. 1996 Aug; 172(2):210-3.
![Page 5: DVT PROPHYLAXIS IN ORTHOPEDIC SURGERIES](https://reader035.vdocuments.mx/reader035/viewer/2022062412/5871114f1a28abac6d8b5d4b/html5/thumbnails/5.jpg)
Indian J Urol. 2009 Jan-Mar; 25(1): 11–16.doi: 10.4103/0970-1591.45531
INCIDENCE OF DVT IN DIFFERENT SURGERIES
Patient group VTE prevalence (%)
Medical patients 10-20
Cardiac patients 15-40
Neurosurgery 15-40
Stroke 20-30
Hip and knee arthroplasty 40-60
Major trauma 40-50
Spinal cord injury 60-80
Critical care patients 10-20
![Page 6: DVT PROPHYLAXIS IN ORTHOPEDIC SURGERIES](https://reader035.vdocuments.mx/reader035/viewer/2022062412/5871114f1a28abac6d8b5d4b/html5/thumbnails/6.jpg)
Strong risk factors
1. Hip or leg fracture
2. Hip or knee replacement
3. Major general surgery
4. Major trauma, including spinal cord injury
![Page 7: DVT PROPHYLAXIS IN ORTHOPEDIC SURGERIES](https://reader035.vdocuments.mx/reader035/viewer/2022062412/5871114f1a28abac6d8b5d4b/html5/thumbnails/7.jpg)
Moderate risk factors
1. Arthroscopic knee surgery
2. Central venous catheterization
3. HRT or OC Pills
4. Malignancy (active or recently treated)
5. Pregnancy
6. Paralytic stroke
7. Prior VTE
8. Thrombophilia (inherited or acquired)
![Page 8: DVT PROPHYLAXIS IN ORTHOPEDIC SURGERIES](https://reader035.vdocuments.mx/reader035/viewer/2022062412/5871114f1a28abac6d8b5d4b/html5/thumbnails/8.jpg)
Weak risk factors
1. Bed rest > 3d
2. Prolonged immobility
3. Advanced age
4. Laparoscopic surgery
5. Obesity
6. Pregnancy
7. Varicose veins
Anderson FA Jr,Spencer FA: Risk factors for venous thromboembolism Circulation107[23, Suppl 1]:I9,2003
![Page 9: DVT PROPHYLAXIS IN ORTHOPEDIC SURGERIES](https://reader035.vdocuments.mx/reader035/viewer/2022062412/5871114f1a28abac6d8b5d4b/html5/thumbnails/9.jpg)
PATHOPHYSIOLOGY
• virchow's triad
![Page 10: DVT PROPHYLAXIS IN ORTHOPEDIC SURGERIES](https://reader035.vdocuments.mx/reader035/viewer/2022062412/5871114f1a28abac6d8b5d4b/html5/thumbnails/10.jpg)
Presentation and Physical Examination
• Calf pain or tenderness
• Swelling + pitting oedema
• Increased skin temperature and fever
• Superficial venous dilatation
![Page 11: DVT PROPHYLAXIS IN ORTHOPEDIC SURGERIES](https://reader035.vdocuments.mx/reader035/viewer/2022062412/5871114f1a28abac6d8b5d4b/html5/thumbnails/11.jpg)
Clinical examination
• Palpate distal pulses
• Evaluate capillary refill .
• Neurologic evaluation
![Page 12: DVT PROPHYLAXIS IN ORTHOPEDIC SURGERIES](https://reader035.vdocuments.mx/reader035/viewer/2022062412/5871114f1a28abac6d8b5d4b/html5/thumbnails/12.jpg)
• Homans sign: pain posterior calf /knee with forced dorsiflexion of foot.
• Moses sign Gentle squeezing of lower part of calf from side to side.
• Neuhofs sign Thickening and deep tenderness elicited while palpating deep in calf muscles
![Page 13: DVT PROPHYLAXIS IN ORTHOPEDIC SURGERIES](https://reader035.vdocuments.mx/reader035/viewer/2022062412/5871114f1a28abac6d8b5d4b/html5/thumbnails/13.jpg)
Wells Clinical Prediction Guide
Variable Wells
Active cancer ( within last 6 months or palliative) 1
Calf swelling >3 cm compared to other 1
Collateral superficial veins 1
Pitting edema 1
Swelling of entire leg 1
![Page 14: DVT PROPHYLAXIS IN ORTHOPEDIC SURGERIES](https://reader035.vdocuments.mx/reader035/viewer/2022062412/5871114f1a28abac6d8b5d4b/html5/thumbnails/14.jpg)
variable wells
Paralysis, paresis, or recent cast immobilization of lower extremities 1
Recently bedridden > 3 days, or major surgery 1
Previous DVT 1
Alternative diagnosis at least as likely deep vein thrombosis-2
Localized pain along distribution of deep venous system 1
![Page 15: DVT PROPHYLAXIS IN ORTHOPEDIC SURGERIES](https://reader035.vdocuments.mx/reader035/viewer/2022062412/5871114f1a28abac6d8b5d4b/html5/thumbnails/15.jpg)
Interpretation
High probability: ≥ 3 (Prevalence of DVT - 53%)
Moderate probability: 1-2 (Prevalence of DVT - 17%)
Low probability: ≤ 0 (Prevalence of DVT - 5%)
Adapted from Anand SS, et al. JAMA. 1998; 279 [14];1094
![Page 16: DVT PROPHYLAXIS IN ORTHOPEDIC SURGERIES](https://reader035.vdocuments.mx/reader035/viewer/2022062412/5871114f1a28abac6d8b5d4b/html5/thumbnails/16.jpg)
Over 20 different VTE risk assessment models
• Individualized point-based scoring models e.g.:CAPRINI PADUA REVISED GENEVA SCORE
• Grouping or “bucket” models:– NICE / NHS guidelines – Classic “3 bucket” model
![Page 17: DVT PROPHYLAXIS IN ORTHOPEDIC SURGERIES](https://reader035.vdocuments.mx/reader035/viewer/2022062412/5871114f1a28abac6d8b5d4b/html5/thumbnails/17.jpg)
![Page 18: DVT PROPHYLAXIS IN ORTHOPEDIC SURGERIES](https://reader035.vdocuments.mx/reader035/viewer/2022062412/5871114f1a28abac6d8b5d4b/html5/thumbnails/18.jpg)
A TOTAL SCORE >4 INDICATES HIGH RISK OF VTE
![Page 19: DVT PROPHYLAXIS IN ORTHOPEDIC SURGERIES](https://reader035.vdocuments.mx/reader035/viewer/2022062412/5871114f1a28abac6d8b5d4b/html5/thumbnails/19.jpg)
![Page 20: DVT PROPHYLAXIS IN ORTHOPEDIC SURGERIES](https://reader035.vdocuments.mx/reader035/viewer/2022062412/5871114f1a28abac6d8b5d4b/html5/thumbnails/20.jpg)
Interpretation of revised Geneva score
0-3 score : low risk
4-10 score : intermediate risk
>11 score : high risk
.
![Page 21: DVT PROPHYLAXIS IN ORTHOPEDIC SURGERIES](https://reader035.vdocuments.mx/reader035/viewer/2022062412/5871114f1a28abac6d8b5d4b/html5/thumbnails/21.jpg)
• Validated in predicting risk
• Can be difficult to use reliably
Caprini Model
![Page 22: DVT PROPHYLAXIS IN ORTHOPEDIC SURGERIES](https://reader035.vdocuments.mx/reader035/viewer/2022062412/5871114f1a28abac6d8b5d4b/html5/thumbnails/22.jpg)
1 point for each risk factors
• Age 41-60
• Swollen legs
• Varicose veins
• Obesity
• Sepsis
• OCP or HRT
• Pregnancy or postpartum
• AMI
• CHF
• Prolonged bed rest
• Prior major surgery
![Page 23: DVT PROPHYLAXIS IN ORTHOPEDIC SURGERIES](https://reader035.vdocuments.mx/reader035/viewer/2022062412/5871114f1a28abac6d8b5d4b/html5/thumbnails/23.jpg)
2 points for each risk factors
• Age 61-74 yrs
• Arthroscopic surgery
• Malignancy
• Laparoscopic surgery
• Immobilisation with plaster cast (<1 month)
![Page 24: DVT PROPHYLAXIS IN ORTHOPEDIC SURGERIES](https://reader035.vdocuments.mx/reader035/viewer/2022062412/5871114f1a28abac6d8b5d4b/html5/thumbnails/24.jpg)
3 points for each risk factor
• Age >75 yrs
• History of DVT /PE
• Positive factor leiden
• Family history of VTE
• Positive lupus anticoagulant
• HIT
• Elevated anticardiolipin antibodies
![Page 25: DVT PROPHYLAXIS IN ORTHOPEDIC SURGERIES](https://reader035.vdocuments.mx/reader035/viewer/2022062412/5871114f1a28abac6d8b5d4b/html5/thumbnails/25.jpg)
5 points for each risk factors
• Stroke (<1 months)
• Elective major lower limb arthroplasty
• Hip ,pelvic , leg fractures(<1 month)
• Spinal cord injury (<1 month)
![Page 26: DVT PROPHYLAXIS IN ORTHOPEDIC SURGERIES](https://reader035.vdocuments.mx/reader035/viewer/2022062412/5871114f1a28abac6d8b5d4b/html5/thumbnails/26.jpg)
PROPHYLAXIS PROCEDURES
1. Mechanical
2. Pharmacological
![Page 27: DVT PROPHYLAXIS IN ORTHOPEDIC SURGERIES](https://reader035.vdocuments.mx/reader035/viewer/2022062412/5871114f1a28abac6d8b5d4b/html5/thumbnails/27.jpg)
Mechanical
1. Physiotherapy
2. Graduated Compression Stockings (GCS)
3. Intermittent Pneumatic Compression Devices (IPC)
and Venous foot pumps (VFP).
4. IVC filters
![Page 28: DVT PROPHYLAXIS IN ORTHOPEDIC SURGERIES](https://reader035.vdocuments.mx/reader035/viewer/2022062412/5871114f1a28abac6d8b5d4b/html5/thumbnails/28.jpg)
Graduated Compression Stockings (GCS)
GRADUATED COMPRESSION STOCKINGS
![Page 29: DVT PROPHYLAXIS IN ORTHOPEDIC SURGERIES](https://reader035.vdocuments.mx/reader035/viewer/2022062412/5871114f1a28abac6d8b5d4b/html5/thumbnails/29.jpg)
Update of
Elastic compression stockings for prevention of deep vein thrombosis. [Cochrane Database Syst Rev. 2010]
19 RCTs
1681 individual patients and 1064 individual legs (2745 analytic units).
9 TRIALS- general surgery,
6 TRIALS- orthopaedic surgery,
1 TRIAL- medical patients.
G c s applied on the day before surgery or on the day of surgery . worn up until discharge or until the patients were fully mobile
![Page 30: DVT PROPHYLAXIS IN ORTHOPEDIC SURGERIES](https://reader035.vdocuments.mx/reader035/viewer/2022062412/5871114f1a28abac6d8b5d4b/html5/thumbnails/30.jpg)
Treatment group (GCS) of 1391 units -126 developed DVT
control group (without GCS) of 1354 units - 282 developed DVT
odds ratio was 0.33 (95% CI) 0.26 to 0.41 (P < 0.00001).
![Page 31: DVT PROPHYLAXIS IN ORTHOPEDIC SURGERIES](https://reader035.vdocuments.mx/reader035/viewer/2022062412/5871114f1a28abac6d8b5d4b/html5/thumbnails/31.jpg)
INTERMITTENT PNEUMATIC COMPRESSION [IPC]
• Inflation Cycle :10-20 secs
• Deflation cycle :30 secs
![Page 32: DVT PROPHYLAXIS IN ORTHOPEDIC SURGERIES](https://reader035.vdocuments.mx/reader035/viewer/2022062412/5871114f1a28abac6d8b5d4b/html5/thumbnails/32.jpg)
• At 40 mm Hg -maximum velocities with calf and/or thigh compression –
Femoral velocity- 35–60 cm/s with augmentations at around 50–250%
popliteal velocities -55 cm/s.
At 120 mm Hg – peak velocities of >100 cm/s in both popliteal and
femoral veins
![Page 33: DVT PROPHYLAXIS IN ORTHOPEDIC SURGERIES](https://reader035.vdocuments.mx/reader035/viewer/2022062412/5871114f1a28abac6d8b5d4b/html5/thumbnails/33.jpg)
• Foot compression has produced more modest results
20–40 cm/s -femoral vein 30–55 cm/s - popliteal vein
![Page 34: DVT PROPHYLAXIS IN ORTHOPEDIC SURGERIES](https://reader035.vdocuments.mx/reader035/viewer/2022062412/5871114f1a28abac6d8b5d4b/html5/thumbnails/34.jpg)
TYPES OF IPC
•.
![Page 35: DVT PROPHYLAXIS IN ORTHOPEDIC SURGERIES](https://reader035.vdocuments.mx/reader035/viewer/2022062412/5871114f1a28abac6d8b5d4b/html5/thumbnails/35.jpg)
A: Venous blood flow velocity in the posterior tibial vein during compression by a foot cuff (velocity/ time
B: Venous blood flow velocity in the femoral vein during compression by a foot cuff (velocity [cm/s] vs. time [1 second per vertical dotted line]).
![Page 36: DVT PROPHYLAXIS IN ORTHOPEDIC SURGERIES](https://reader035.vdocuments.mx/reader035/viewer/2022062412/5871114f1a28abac6d8b5d4b/html5/thumbnails/36.jpg)
Problems in IPC
Improperly fitted compression stockings
reversed pressure gradient
higher incidence of VTE
![Page 37: DVT PROPHYLAXIS IN ORTHOPEDIC SURGERIES](https://reader035.vdocuments.mx/reader035/viewer/2022062412/5871114f1a28abac6d8b5d4b/html5/thumbnails/37.jpg)
CONTRAINDICATION OF IPC
• Severe arteriosclerosis
• Severe CHF
• Known acute DVT
• Gangrene
• Dermatitis
• Skin grafting
![Page 38: DVT PROPHYLAXIS IN ORTHOPEDIC SURGERIES](https://reader035.vdocuments.mx/reader035/viewer/2022062412/5871114f1a28abac6d8b5d4b/html5/thumbnails/38.jpg)
The Cochrane Peripheral Vascular Diseases Group Trials
RCT with 121 study participants comparing 2 types of IPC devices
• no cases of symptomatic DVT or PE during first 3 weeks after THR.
• calf-thigh pneumatic compression more effective
for reducing thigh swelling during early post-operative stage
Equal evidence regarding both types
![Page 39: DVT PROPHYLAXIS IN ORTHOPEDIC SURGERIES](https://reader035.vdocuments.mx/reader035/viewer/2022062412/5871114f1a28abac6d8b5d4b/html5/thumbnails/39.jpg)
DVT PUMP
• SET Pressures:
uniform thigh and calf / uniform calf garment 40 mmhg
sequential thigh and calf /sequential calf garment 45 mmhg
foot garment 130 mmhg
![Page 40: DVT PROPHYLAXIS IN ORTHOPEDIC SURGERIES](https://reader035.vdocuments.mx/reader035/viewer/2022062412/5871114f1a28abac6d8b5d4b/html5/thumbnails/40.jpg)
IVC filters
• FDA approved
• Ideal for young patients with reversible
PE risk factors
![Page 41: DVT PROPHYLAXIS IN ORTHOPEDIC SURGERIES](https://reader035.vdocuments.mx/reader035/viewer/2022062412/5871114f1a28abac6d8b5d4b/html5/thumbnails/41.jpg)
Indications• Proven VTE
• Recurrent VTE
• Contraindications to anticoagulation
• Short Term Risk of PE/Short Term contraindication of
anticoagulation :retrievable filter
• Uncertain Risk of PE and/or lack of control for anticoagulation :
Permanent Filter
• Long Term Risk of PE/Recurrent PE/Recurrent DVT: Permanent Filter
![Page 42: DVT PROPHYLAXIS IN ORTHOPEDIC SURGERIES](https://reader035.vdocuments.mx/reader035/viewer/2022062412/5871114f1a28abac6d8b5d4b/html5/thumbnails/42.jpg)
SIDE EFFECTS
• Device-associated morbidity
• Device migration
• Filter embolization
• Filter fracture
• Insertion-site thrombosis
• Perforation of the vena cava
• Recurrent DVT
• Recurrent PE
• Thrombotic complications
• Vena cava thrombosis
![Page 43: DVT PROPHYLAXIS IN ORTHOPEDIC SURGERIES](https://reader035.vdocuments.mx/reader035/viewer/2022062412/5871114f1a28abac6d8b5d4b/html5/thumbnails/43.jpg)
Pharmacological:
1. Oral antiplatelet agents
2. Injectable low-molecular-weight heparins
3. Injectable unfractionated heparin
4. Injectable or oral factor Xa inhibitors
5. Injectable or oral direct thrombin inhibitors
6. Oral vitamin K antagonists
![Page 44: DVT PROPHYLAXIS IN ORTHOPEDIC SURGERIES](https://reader035.vdocuments.mx/reader035/viewer/2022062412/5871114f1a28abac6d8b5d4b/html5/thumbnails/44.jpg)
Oral antiplatelet agents
• Aspirin Permanently inhibits COX-1 and COX-2
• Dipyridamole Inhibits PDE; increases Camp
• Ticlopidine• Clopidrgrel• Abciximab • Eptifibatide • Tirofiban
![Page 45: DVT PROPHYLAXIS IN ORTHOPEDIC SURGERIES](https://reader035.vdocuments.mx/reader035/viewer/2022062412/5871114f1a28abac6d8b5d4b/html5/thumbnails/45.jpg)
Aspirin
• Dosage : 75 mg OD
• ACCP and AAOS guidelines do not include aspirin in prevention of VTE
• Present indications:
1.elective TKR
2.elective THR
3.contraindication to other pharmacologic prophylaxis
![Page 46: DVT PROPHYLAXIS IN ORTHOPEDIC SURGERIES](https://reader035.vdocuments.mx/reader035/viewer/2022062412/5871114f1a28abac6d8b5d4b/html5/thumbnails/46.jpg)
Contraindications to Antiplatelet Therapy
- Recent thoracic, abdominal, or cns surgery
-Recent CVA , trauma, or neoplasm
-Bleeding ulcer
-Hypertension
-Anticipated invasive procedures
-Concurrent hemostatic dysfunction
![Page 47: DVT PROPHYLAXIS IN ORTHOPEDIC SURGERIES](https://reader035.vdocuments.mx/reader035/viewer/2022062412/5871114f1a28abac6d8b5d4b/html5/thumbnails/47.jpg)
Heparin
• Types :
Un fractionated heparin(UFH) : inhibit factor II and X
Dose for DVT prophylaxis: 5000 u sc every 8 to 12 hours
Monitoring : aPTT
More risk for bleeding and heparin induced thrombocytopenia(8%)
Antidote: Protamine sulphate
![Page 48: DVT PROPHYLAXIS IN ORTHOPEDIC SURGERIES](https://reader035.vdocuments.mx/reader035/viewer/2022062412/5871114f1a28abac6d8b5d4b/html5/thumbnails/48.jpg)
LMWH• Examples: enoxaparin, dalteparin, tinzaparin
• Inhibit thrombin only
• Dose in prophylaxis : 40 mg in 0.4 mL SC OD
• Lesser risk of and bleeding HIT
• No need to regular monitoring
• No antidote
![Page 49: DVT PROPHYLAXIS IN ORTHOPEDIC SURGERIES](https://reader035.vdocuments.mx/reader035/viewer/2022062412/5871114f1a28abac6d8b5d4b/html5/thumbnails/49.jpg)
Baseline Postoperative Risks of VTE Outcomes in the Absence of Pharmacological Prophylaxis
• Outcome Total Hip Replacement
Strength of Evidence(THR)
Total Knee Replacement
Strength of Evidence(TKR)
Pulmonary embolism
6% Low 1% Low
Deep vein thrombosis
39% Low 46% Low
Major bleeding
1% Moderate 3% Low
Minor bleeding
5% Low 5% Moderate
Sobieraj DM, et al. Comparative Effectiveness Review No. 49. Available at www.effectivehealthcare.ahrq.gov/thrombo.cfm
![Page 50: DVT PROPHYLAXIS IN ORTHOPEDIC SURGERIES](https://reader035.vdocuments.mx/reader035/viewer/2022062412/5871114f1a28abac6d8b5d4b/html5/thumbnails/50.jpg)
Comparative Effectiveness of Pharmacological Prophylaxis Agents: LMWH Versus UFH
Comparators DVT PE Major Bleeding
Heparin-induced Thrombo-cytopenia
LMWH vs. UFH
Decreased risk by 20%
RR 0.80
Decreased odds by 52%
OR 0.48
Decreased odds by 35%
OR 0.57
Decreased odds by 88%
OR 0.12
Sobieraj DM, et al. Comparative Effectiveness Review No. 49. Available at www.effectivehealthcare.ahrq.gov/thrombo.cfm
![Page 51: DVT PROPHYLAXIS IN ORTHOPEDIC SURGERIES](https://reader035.vdocuments.mx/reader035/viewer/2022062412/5871114f1a28abac6d8b5d4b/html5/thumbnails/51.jpg)
warfarin
• Vitamin k antagonist
• Cause defective coagulation
• Slow in onset
• Good oral absorption
• Monitor with PT and INR
![Page 52: DVT PROPHYLAXIS IN ORTHOPEDIC SURGERIES](https://reader035.vdocuments.mx/reader035/viewer/2022062412/5871114f1a28abac6d8b5d4b/html5/thumbnails/52.jpg)
Comparative Effectiveness of Pharmacological Prophylaxis Agents: LMWH Versus Warfarin
Comparators DVT Proximal DVT
SymptomaticVTE
PE
LMWH vs. warfarin
Decreased risk by 34%
RR 0.66
No difference;
RR 0.63
No difference;
OR 1.00
No difference;
OR 1.11
Sobieraj DM, et al. Comparative Effectiveness Review No. 49. Available at www.effectivehealthcare.ahrq.gov/thrombo.cfm
![Page 53: DVT PROPHYLAXIS IN ORTHOPEDIC SURGERIES](https://reader035.vdocuments.mx/reader035/viewer/2022062412/5871114f1a28abac6d8b5d4b/html5/thumbnails/53.jpg)
Fondaparinux
– Synthetic Factor Xa inhibitor
– FDA approved for prophylaxis, treatment
• Prophylaxis: 2.5/d SC
• Treatment: weight based 5, 7.5 or 10/d SC
– Start warfarin simultaneously, continue 5-7 days as with heparin
• Avoid with GFR < 30
![Page 54: DVT PROPHYLAXIS IN ORTHOPEDIC SURGERIES](https://reader035.vdocuments.mx/reader035/viewer/2022062412/5871114f1a28abac6d8b5d4b/html5/thumbnails/54.jpg)
Comparative Effectiveness of Pharmacological Prophylaxis Agents: Enoxaparin Versus Fondaparinux
Comparators DVT Symptomatic VTE
PE Major Bleeding
Enoxaparinvs. fondaparinux
Relative risk is higher for enoxaparinby 99%
RR 1.99
No difference;
OR 0.70
No difference
OR 3.34
Decreased odds by 35%
OR 0.65
Sobieraj DM, et al. Comparative Effectiveness Review No. 49. Available at www.effectivehealthcare.ahrq.gov/thrombo.cfm
![Page 55: DVT PROPHYLAXIS IN ORTHOPEDIC SURGERIES](https://reader035.vdocuments.mx/reader035/viewer/2022062412/5871114f1a28abac6d8b5d4b/html5/thumbnails/55.jpg)
Ximelagatran• Direct thrombin inhibitors
• Alternative to warfarin
– Oral - fixed dose
• Acute clot or orthopedic prophylaxis: 36 mg bid
• Secondary prevention: 24 mg bid
– No monitoring, no initial heparin
• Safety questions
– No antidote
– Can elevate LFTs
![Page 56: DVT PROPHYLAXIS IN ORTHOPEDIC SURGERIES](https://reader035.vdocuments.mx/reader035/viewer/2022062412/5871114f1a28abac6d8b5d4b/html5/thumbnails/56.jpg)
NICE Guidelines 2015
Elective hip / knee replacement
Start mechanical VTE prophylaxis at admission
• anti embolism stockings (GCS)‑
• foot impulse devices
• intermittent pneumatic compression (IPC)devices
Continue mechanical VTE prophylaxis until the patient no longer has significantly reduced mobility.
![Page 57: DVT PROPHYLAXIS IN ORTHOPEDIC SURGERIES](https://reader035.vdocuments.mx/reader035/viewer/2022062412/5871114f1a28abac6d8b5d4b/html5/thumbnails/57.jpg)
If no contraindications, start pharmacological VTE prophylaxis after surgery
• dabigatran etexilate 1–4 hours after surgery
• fondaparinux sodium 6 hours after
• LMWH 6–12 hours after
• Rivaroxaban 6–10 hours after
• UFH (for renal failure patients) 6–12 hours after
Continue pharmacological VTE prophylaxis for 28–35 days in hip replacements Continue pharmacological VTE prophylaxis for 10-14 days in knee replacements
![Page 58: DVT PROPHYLAXIS IN ORTHOPEDIC SURGERIES](https://reader035.vdocuments.mx/reader035/viewer/2022062412/5871114f1a28abac6d8b5d4b/html5/thumbnails/58.jpg)
• Hip fractures:
Start mechanical VTE prophylaxis at admission
•Anti embolism stockings ‑
•Foot impulse devices
•Intermittent pneumatic compression devices (thigh or knee length).
Continue mechanical VTE prophylaxis until the patient no longer has significantly
reduced mobility.
![Page 59: DVT PROPHYLAXIS IN ORTHOPEDIC SURGERIES](https://reader035.vdocuments.mx/reader035/viewer/2022062412/5871114f1a28abac6d8b5d4b/html5/thumbnails/59.jpg)
If no contraindications, start pharmacological VTE prophylaxis after surgery
• fondaparinux sodium not recommnded pre op,
can be given 6 hrs post op
• LMWH start at admission,
stop 12 hr before restart 6–12 hours after surgery
• Rivaroxaban 6–10 hours after
• UFH (for CRF) start at admission
stop 12 hr before Restart 6–12 hours after surgery
• Continue pharmacological VTE prophylaxis for 28–35 days
![Page 60: DVT PROPHYLAXIS IN ORTHOPEDIC SURGERIES](https://reader035.vdocuments.mx/reader035/viewer/2022062412/5871114f1a28abac6d8b5d4b/html5/thumbnails/60.jpg)
Other orthopaedic surgery
Start mechanical VTE prophylaxis at admission.
• Anti embolism stockings ‑
• Foot impulse devices
• Intermittent pneumatic compression devices (thigh or knee length).
Continue mechanical VTE prophylaxis until the patient no longer has significantly
reduced mobility.
![Page 61: DVT PROPHYLAXIS IN ORTHOPEDIC SURGERIES](https://reader035.vdocuments.mx/reader035/viewer/2022062412/5871114f1a28abac6d8b5d4b/html5/thumbnails/61.jpg)
.Pharmacological VTE prophylaxis 6–12 hours after surgery.
• LMWH
• UFH (for renal failure).
• Continue pharmacological VTE prophylaxis until patient no longer has
significantly reduced mobility.
![Page 62: DVT PROPHYLAXIS IN ORTHOPEDIC SURGERIES](https://reader035.vdocuments.mx/reader035/viewer/2022062412/5871114f1a28abac6d8b5d4b/html5/thumbnails/62.jpg)
DVT prophylaxis : ORTHOPEDICS SURGERY
• Low risk
– Early ambulation
• Moderate risk
– UFH 5000 u sc bid or LMWH, IPC
• High risk
– LMWH - may combine with IPC
AAOS Clinical Practice Guideline
![Page 63: DVT PROPHYLAXIS IN ORTHOPEDIC SURGERIES](https://reader035.vdocuments.mx/reader035/viewer/2022062412/5871114f1a28abac6d8b5d4b/html5/thumbnails/63.jpg)
Schematic of estimated incidence rates for LMWH and no prophylaxis for major orthopaedic surgery
• Ref:Prevention of VTE in orthopedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
• Falck-Ytter Y1, Francis CW, Johanson NA, Curley C, Dahl OE, Schulman S, Ortel TL, Pauker SG, Colwell CW Jr;
![Page 64: DVT PROPHYLAXIS IN ORTHOPEDIC SURGERIES](https://reader035.vdocuments.mx/reader035/viewer/2022062412/5871114f1a28abac6d8b5d4b/html5/thumbnails/64.jpg)
Systematic Review – Regarding DVT Prophylaxis
Meta regression analysis
Compare other therapies to enoxaparin for prevention of VTE following THR
Dranitsaris 2011 http://www.aaos.org/
![Page 65: DVT PROPHYLAXIS IN ORTHOPEDIC SURGERIES](https://reader035.vdocuments.mx/reader035/viewer/2022062412/5871114f1a28abac6d8b5d4b/html5/thumbnails/65.jpg)
![Page 66: DVT PROPHYLAXIS IN ORTHOPEDIC SURGERIES](https://reader035.vdocuments.mx/reader035/viewer/2022062412/5871114f1a28abac6d8b5d4b/html5/thumbnails/66.jpg)
Low-molecular-weight heparin and intermittent pneumatic compression for thromboprophylaxis in critical patients
BING WAN, et al Oct 13. 2015 PMC
• 500 patients were divided into four groups
• IPC( int. Pneumatic compression) 95
• LMWH 185
• LMWH + IPC 75
• control 145
Doppler study diagnosis done
![Page 67: DVT PROPHYLAXIS IN ORTHOPEDIC SURGERIES](https://reader035.vdocuments.mx/reader035/viewer/2022062412/5871114f1a28abac6d8b5d4b/html5/thumbnails/67.jpg)
Incidence of DVT, PE and complications of treatment in the four groups.
Group No. of patients DVT cases PE cases Bleeding cases
IPC 95 9 28 0
LMWH 185 31 4 18
LMWH + IPC 75 0 0 3
Control 145 49 29 0
![Page 68: DVT PROPHYLAXIS IN ORTHOPEDIC SURGERIES](https://reader035.vdocuments.mx/reader035/viewer/2022062412/5871114f1a28abac6d8b5d4b/html5/thumbnails/68.jpg)
conclusion
• LMWH combined with IPC exhibited an excellent prophylactic effect against DVT and PE.
• RR : 0.281 for IPC,
• RR: 0.49 for LMWH.
![Page 69: DVT PROPHYLAXIS IN ORTHOPEDIC SURGERIES](https://reader035.vdocuments.mx/reader035/viewer/2022062412/5871114f1a28abac6d8b5d4b/html5/thumbnails/69.jpg)
Comparative efficacy and safety of anticoagulants and aspirin for extended treatment of venous thromboembolism: A network meta-analysis
Diana M. Sobieraj et al
systematic literature search and searching of reference lists
identify RCT of patients completed initial anticoagulant treatment for VTE
randomized for the extension study
comparison of anticoagulant treatment to placebo
![Page 70: DVT PROPHYLAXIS IN ORTHOPEDIC SURGERIES](https://reader035.vdocuments.mx/reader035/viewer/2022062412/5871114f1a28abac6d8b5d4b/html5/thumbnails/70.jpg)
.• Ten trials (n = 11,079) were included.
• Apixaban ,dabigatran, rivaroxaban, idraparinux and vitamin
K antagonists (VKA) reduced risk of VTE recurrence
compared to placebo.
![Page 71: DVT PROPHYLAXIS IN ORTHOPEDIC SURGERIES](https://reader035.vdocuments.mx/reader035/viewer/2022062412/5871114f1a28abac6d8b5d4b/html5/thumbnails/71.jpg)
COMPARATIVE EFFICACY AND SAFETY OF NEW ORAL ANTICOAGULANTS(NOAC) VERSUS WARFARIN FOR LONG-TERM TREATMENT OF VENOUS THROMBOEMBOLISM: A META-ANALYSIS
Ajay Vallakati et al
• We searched PubMed, Cochrane library and Embase for RCTs comparing
NOACs (dabigatran, apixaban, rivaroxaban, and edoxaban) with placebo or
warfarin for long-term treatment of VTE
![Page 72: DVT PROPHYLAXIS IN ORTHOPEDIC SURGERIES](https://reader035.vdocuments.mx/reader035/viewer/2022062412/5871114f1a28abac6d8b5d4b/html5/thumbnails/72.jpg)
5 RCTs (n=16117) compared
NOACs (n=8484)
with either placebo (n=2085)
or warfarin (n=5548).
NOACs significantly reduced the risk of VTE
when compared to placebo/ warfarin (OR: 0.33; 95% CI, 0.13 −0.87)
• .
![Page 73: DVT PROPHYLAXIS IN ORTHOPEDIC SURGERIES](https://reader035.vdocuments.mx/reader035/viewer/2022062412/5871114f1a28abac6d8b5d4b/html5/thumbnails/73.jpg)
THANK YOU
•.